4.7 Article

Drug permeation and barrier damage in Leishmania-infected mouse skin

期刊

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
卷 71, 期 6, 页码 1578-1585

出版社

OXFORD UNIV PRESS
DOI: 10.1093/jac/dkw012

关键词

-

资金

  1. Bloomsbury Colleges London
  2. UCL

向作者/读者索取更多资源

Objectives: Pathological disorder can disrupt the barrier integrity of the skin, thereby altering the drug delivery from topical formulations to the target site. Cutaneous Leishmaniasis (CL) is an infection of the dermal Layers of the skin and manifests as a variety of skin Lesions from defined nodular forms to plaques and chronic ulcers. The aim of this work was to characterize the physiology and barrier integrity of the Leishmania-infected BALB/c mouse skin and how they impacted delivery of drugs into the skin. Methods: A histological evaluation of the structural differences between uninfected and infected skin was performed using haematoxylin/eosin, elastic Van Gieson and Iba-1 stains. As a CL nodule developed and progressed, the skin pH, hydration and trans-epidermal water Loss (TEWL) were recorded. Finally, Franz diffusion cells were used to evaluate the influence of the infection on drug delivery through the skin. Results: We found: (i) structural changes in both the epidermal and dermal Layers due to the ingress of inflammatory cells, as shown by immunohistochemistry; (ii) a significant increase in TEWL; and (iii) significantly higher permeation of the model permeants caffeine and ibuprofen and the antileishmanial drugs buparvaquone and paromomycin, for Leishmania-infected skin compared with uninfected skin. The infection had no measurable influence on skin pH and hydration. Conclusions: We report profound changes in the skin barrier physiology, function and permeability to drugs of Leishmania-infected skin.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Microbiology

Topical Treatment for Cutaneous Leishmaniasis: Dermato-Pharmacokinetic Lead Optimization of Benzoxaboroles

Katrien Van Bocxlaer, Eric Gaukel, Deirdre Hauser, Seong Hee Park, Sara Schock, Vanessa Yardley, Ryan Randolph, Jacob J. Plattner, Tejal Merchant, Simon L. Croft, Robert T. Jacobs, Stephen A. Wring

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)

Article Chemistry, Medicinal

Synthesis, Profiling, and in Vivo Evaluation of Cyclopeptides Containing N-Methyl Amino Acids as Antiplasmodial Agents

Catherine Fagundez, Diver Sellanes, Stella Pena, Laura Scarone, Anna C. C. Aguiar, Juliana O. de Souza, Rafael V. C. Guido, Lindsay Stewart, Vanessa Yardley, Sabine Ottilie, Elizabeth A. Winzeler, Francisco-J. Gamo, Laura M. Sanz, Gloria L. Serra

ACS MEDICINAL CHEMISTRY LETTERS (2019)

Article Parasitology

Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis

Katrien Van Bocxlaer, Diana Caridha, Chad Black, Brian Vesely, Susan Leed, Richard J. Sciotti, Gert-Jan Wijnant, Vanessa Yardley, Stephanie Braillard, Charles E. Mowbray, Jean-Robert Ioset, Simon L. Croft

INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE (2019)

Article Infectious Diseases

A single dose of antibody-drug conjugate cures a stage 1 model of African trypanosomiasis

Paula MacGregor, Andrea L. Gonzalez-Munoz, Fatoumatta Jobe, Martin C. Taylor, Steven Rust, Alan M. Sandercock, Olivia J. S. Macleod, Katrien Van Bocxlaer, Amanda F. Francisco, Francois D'Hooge, Arnaud Tiberghien, Conor S. Barry, Philip Howard, Matthew K. Higgins, Tristan J. Vaughan, Ralph Minter, Mark Carrington

PLOS NEGLECTED TROPICAL DISEASES (2019)

Article Microbiology

Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous Leishmaniasis

Gert-Jan Wijnant, Simon L. Croft, Raul de la Flor, Mo Alavijeh, Vanessa Yardley, Stephanie Braillard, Charles Mowbray, Katrien Van Bocxlaer

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)

Review Parasitology

Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis

Diana Caridha, Brian Vesely, Katrien van Bocxlaer, Byron Arana, Charles E. Mowbray, Sima Rafati, Silvia Uliana, Rosa Reguera, Mara Kreishman-Deitrick, Richard Sciotti, Pierre Buffet, Simon L. Croft

INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE (2019)

Article Biochemical Research Methods

An efficient and novel technology for the extraction of parasite genomic DNA from whole blood or culture

David J. Clark, Catherine M. Moore, Marc Flanagan, Katrien Van Bocxlaer, Evangelia-Theophano Piperaki, Vanessa Yardley, Simon L. Croft, John Tyson, Sam P. Whitehouse, Jonathan O'Halloran, Sanjeev Krishna, Henry M. Staines

BIOTECHNIQUES (2020)

Review Immunology

Leishmaniasis immunopathology-impact on design and use of vaccines, diagnostics and drugs

Paul M. Kaye, Israel Cruz, Albert Picado, Katrien Van Bocxlaer, Simon L. Croft

SEMINARS IN IMMUNOPATHOLOGY (2020)

Article Biochemistry & Molecular Biology

Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis

Alaa Riezk, Katrien Van Bocxlaer, Vanessa Yardley, Sudaxshina Murdan, Simon L. Croft

MOLECULES (2020)

Article Multidisciplinary Sciences

Characterization of a new Leishmania major strain for use in a controlled human infection model

Helen Ashwin, Jovana Sadlova, Barbora Vojtkova, Tomas Becvar, Patrick Lypaczewski, Eli Schwartz, Elizabeth Greensted, Katrien Van Bocxlaer, Marion Pasin, Kai S. Lipinski, Vivak Parkash, Greg Matlashewski, Alison M. Layton, Charles J. Lacey, Charles L. Jaffe, Petr Volf, Paul M. Kaye

Summary: Leishmaniasis is considered a vaccine-preventable disease, but costs and uncertainty hinder progress in vaccine development. Controlled human infection models offer a way to speed up vaccine development and gain better understanding of disease pathogenesis.

NATURE COMMUNICATIONS (2021)

Article Pharmacology & Pharmacy

Film-Forming Systems for the Delivery of DNDI-0690 to Treat Cutaneous Leishmaniasis

Katrien Van Bocxlaer, Kerri-Nicola McArthur, Andy Harris, Mo Alavijeh, Stephanie Braillard, Charles E. Mowbray, Simon L. Croft

Summary: In cutaneous leishmaniasis, using film-forming systems for drug delivery shows potential advantages in reducing adverse effects and improving treatment adherence. However, the efficacy of specific compounds like DNDI-0690 using this system requires further investigation and consideration.

PHARMACEUTICS (2021)

Article Infectious Diseases

Efficacy of oleylphosphocholine in experimental cutaneous leishmaniasis

Katrien Van Bocxlaer, Jodie Dixon, Johannes J. Platteeuw, Dennie van den Heuvel, Kerri-Nicola Mcarthur, Andy Harris, Mo Alavijeh, Simon L. Croft, Vanessa Yardley

Summary: A drug called OLPC has demonstrated potent activity against CL-causing Leishmania species, and could be a promising alternative to miltefosine treatment for cutaneous leishmaniasis.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Review Biochemistry & Molecular Biology

Pharmacokinetics and pharmacodynamics in the treatment of cutaneous leishmaniasis - challenges and opportunities

Katrien Van Bocxlaer, Simon L. Croft

Summary: Treatment of cutaneous leishmaniasis involves the release, permeation and accumulation of active compounds in the skin. Evaluating the pharmacodynamic activity of drugs against parasites is relatively straightforward, but understanding the pharmacokinetic processes within the skin is more complex due to various factors such as skin structure and drug distribution.

RSC MEDICINAL CHEMISTRY (2021)

Article Microbiology

Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis

Gert-Jan Wijnant, Katrien Van Bocxlaer, Vanessa Yardley, Andy Harris, Sudaxshina Murdan, Simon L. Croft

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)

暂无数据